We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RPS11
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • RPS11
CANCER MELANOMA Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
SKCM TCGA PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Melanoma
Human cancer
Skin cuteneous melanoma
SKIN CUTENEOUS MELANOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

RPS11 is not prognostic in Skin Cuteneous Melanoma (TCGA)


Stage:


Survival analysis
Current cut offi

Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.

:
Best expression cut offi

Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .

When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.

: 2151.63
Median expressioni

Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.

: N/A
Median follow up timei

Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.

: N/A
P scorei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

N/A
3-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
3-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

N/A
TCGA RNA samplesi

RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average pTPM 3046.8
Number of samples 99
Samples
Sample Description pTPM
TCGA-D9-A4Z3-01A 73 years, female, white, stage:Stage IIIC, alive, 505 days 10875.2
TCGA-ER-A42H-01A 76 years, male, white, stage:'--, dead, 426 days 9510.6
TCGA-EB-A41B-01A 76 years, female, white, stage:Stage IIC, alive, 291 days 9254.5
TCGA-EB-A3XE-01A 77 years, female, white, stage:Stage IIA, alive, 180 days 7108.2
TCGA-EB-A5UM-01A 48 years, female, white, stage:Stage IIC, alive, 779 days 6743.6
TCGA-BF-A3DN-01A 81 years, female, white, stage:Stage IIIC, alive, 717 days 5916.1
TCGA-BF-A5EO-01A 65 years, male, white, stage:Stage IIC, alive, 703 days 5623.3
TCGA-EB-A4OY-01A 65 years, female, white, stage:Stage IIIB, alive, 977 days 5461.4
TCGA-EB-A4P0-01A 82 years, male, white, stage:Stage IIC, dead, 326 days 5402.3
TCGA-EB-A5SE-01A 73 years, male, white, stage:Stage IIB, dead, 401 days 5241.6
TCGA-IH-A3EA-01A 61 years, male, white, stage:Stage IIC, alive, 524 days 5210.1
TCGA-XV-AAZW-01A 62 years, female, white, stage:Stage II, dead, 393 days 5128.3
TCGA-EB-A42Y-01A 73 years, female, asian, stage:Stage IIC, dead, 721 days 5113.4
TCGA-EB-A85J-01A 66 years, female, white, stage:Stage IIB, alive, 360 days 5087.8
TCGA-BF-AAP8-01A 58 years, male, white, stage:Stage IIC, alive, 447 days 5001.9
TCGA-EB-A82C-01A 70 years, female, asian, stage:Stage IIC, alive, 17 days 4857.1
TCGA-EB-A4XL-01A 56 years, female, white, stage:Stage IIC, alive, 777 days 4812.2
TCGA-EB-A6QZ-01A 76 years, female, white, stage:Stage IIA, dead, 352 days 4808.0
TCGA-ER-A2NF-01A 53 years, male, white, stage:Stage IIIB, dead, 877 days 4563.3
TCGA-EB-A299-01A 63 years, male, white, stage:Stage IIA, alive, 378 days 4431.2
TCGA-BF-AAP1-01A 86 years, male, white, stage:Stage IIC, alive, 409 days 4224.2
TCGA-FS-A1ZN-01A 43 years, male, white, stage:Stage IIIA, dead, 730 days 4150.0
TCGA-EB-A3XF-01A 57 years, male, white, stage:Stage IIC, alive, 278 days 4119.8
TCGA-BF-A9VF-01A 77 years, male, white, stage:Stage IIC, alive, 440 days 4052.8
TCGA-ER-A196-01A 64 years, female, white, stage:Stage IIC, alive, 1785 days 3994.0
TCGA-EB-A550-01A 75 years, female, white, stage:Stage IIC, dead, 264 days 3948.7
TCGA-EB-A44P-01A 58 years, female, white, stage:Stage IIC, alive, 741 days 3932.8
TCGA-GF-A2C7-01A 48 years, male, white, stage:Stage IIC, alive, 21 days 3917.5
TCGA-BF-A1PV-01A 74 years, female, white, stage:Stage IIC, alive, 14 days 3891.9
TCGA-EB-A57M-01A 56 years, male, asian, stage:Stage IIIB, dead, 472 days 3840.8
TCGA-EB-A5VU-01A 56 years, male, asian, stage:Stage IIIB, dead, 321 days 3776.4
TCGA-BF-A3DL-01A 84 years, female, white, stage:Stage IIIB, alive, 769 days 3605.2
TCGA-XV-AAZY-01A 76 years, female, white, stage:Stage IIIC, alive, 405 days 3503.1
TCGA-EB-A24D-01A 72 years, male, white, stage:Stage IIIB, alive, 645 days 3422.2
TCGA-EB-A4OZ-01A 41 years, female, white, stage:Stage IIIC, alive, 620 days 3418.1
TCGA-ER-A2NB-01A 57 years, male, white, stage:Stage IIIB, dead, 857 days 3410.0
TCGA-EB-A3XC-01A 74 years, male, white, stage:Stage IIC, alive, 650 days 3400.6
TCGA-EB-A82B-01A 58 years, female, asian, stage:Stage III, alive, 390 days 3346.3
TCGA-EB-A3XD-01A 53 years, female, white, stage:Stage IIC, alive, 1160 days 3324.8
TCGA-BF-A5EP-01A 75 years, female, white, stage:Stage IIIC, alive, 335 days 3253.7
TCGA-EB-A4IS-01A 77 years, male, white, stage:Stage IIB, alive, 774 days 3244.3
TCGA-GN-A4U5-01A 61 years, female, white, stage:Stage IB, alive, 1156 days 3219.8
TCGA-D9-A4Z5-01A 68 years, male, white, stage:Stage IIB, alive, 218 days 3204.6
TCGA-BF-AAP2-01A 62 years, male, white, stage:Stage IIB, alive, 405 days 3136.4
TCGA-ER-A19K-01A 79 years, female, white, stage:Stage IIC, dead, 469 days 3118.9
TCGA-BF-A1PX-01A 56 years, male, white, stage:Stage IIIB, dead, 282 days 3118.1
TCGA-EB-A4IQ-01A 42 years, female, asian, stage:Stage IIIB, dead, 636 days 3064.7
TCGA-EB-A6R0-01A 58 years, female, white, stage:Stage IIC, dead, 608 days 2942.6
TCGA-BF-AAOU-01A 73 years, female, white, stage:Stage IIC, alive, 476 days 2925.3
TCGA-XV-AAZV-01A 56 years, female, white, stage:Stage II, alive, 412 days 2881.4
TCGA-EB-A44O-01A 69 years, male, white, stage:Stage IIB, alive, 81 days 2862.7
TCGA-XV-A9W5-01A 51 years, male, white, stage:Not Reported, alive, 392 days 2838.5
TCGA-DA-A960-01A 73 years, male, white, stage:Stage IIB, alive, 804 days 2829.2
TCGA-EB-A51B-01A 53 years, male, white, stage:Stage IIC, alive, 931 days 2793.3
TCGA-D3-A5GT-01A 43 years, male, white, stage:Stage IIIC, alive, 487 days 2773.3
TCGA-BF-AAOX-01A 83 years, male, white, stage:Stage IIC, alive, 444 days 2746.8
TCGA-BF-AAP6-01A 55 years, male, white, stage:Stage III, alive, 325 days 2715.3
TCGA-BF-A5EQ-01A 63 years, male, white, stage:Stage IIC, alive, 323 days 2579.8
TCGA-BF-A1PZ-01A 71 years, female, white, stage:Stage IIB, alive, 853 days 2566.9
TCGA-GN-A263-01A 24 years, male, white, stage:Stage IV, dead, 467 days 2564.7
TCGA-FR-A3R1-01A 69 years, male, white, stage:Stage IIC, alive, 685 days 2401.7
TCGA-EB-A1NK-01A 48 years, male, white, stage:Stage IIC, alive, 1039 days 2280.6
TCGA-BF-A1Q0-01A 80 years, male, white, stage:Stage IIC, alive, 831 days 2277.2
TCGA-BF-A5ES-01A 76 years, female, white, stage:Stage IIC, alive, 490 days 2187.5
TCGA-EB-A431-01A 34 years, male, white, stage:Stage IIC, alive, 568 days 2181.0
TCGA-BF-AAP4-01A 61 years, male, white, stage:Stage IIC, alive, 335 days 2151.6
TCGA-EB-A5FP-01A 65 years, female, white, stage:Stage IV, dead, 454 days 2114.1
TCGA-FR-A728-01A 54 years, female, white, stage:Stage IIIB, alive, 583 days 2050.2
TCGA-EB-A44N-01A 59 years, male, white, stage:Stage IIC, dead, 205 days 1999.0
TCGA-BF-A3DJ-01A 36 years, female, white, stage:Stage IIIB, alive, 464 days 1917.4
TCGA-EB-A551-01A 78 years, female, white, stage:Stage IIIC, alive, 590 days 1610.2
TCGA-EB-A85I-01A 66 years, male, white, stage:Stage IIC, alive, 362 days 1583.3
TCGA-ER-A19T-01A 51 years, male, white, stage:Stage IV, dead, 270 days 1544.8
TCGA-EB-A3XB-01A 63 years, male, white, stage:Stage II, alive, 796 days 1516.4
TCGA-XV-A9W2-01A 81 years, male, white, stage:Stage I, alive, 417 days 1511.8
TCGA-BF-A5ER-01A 63 years, male, white, stage:Stage IIC, alive, 327 days 1358.2
TCGA-BF-A3DM-01A 63 years, male, white, stage:Stage IIA, alive, 601 days 1326.4
TCGA-FW-A5DX-01A 71 years, male, white, stage:Stage IIIC, alive, 640 days 1241.9
TCGA-GF-A769-01A 39 years, male, white, stage:Stage IIC, dead, 1070 days 1157.8
TCGA-ER-A194-01A 77 years, male, white, stage:'--, dead, 1354 days 1093.1
TCGA-BF-AAP7-01A 76 years, female, white, stage:Stage IIC, alive, 318 days 1018.9
TCGA-EB-A97M-01A 66 years, male, white, stage:Stage IIC, alive, 414 days 987.5
TCGA-BF-A1PU-01A 46 years, female, white, stage:Stage IIC, alive, 387 days 878.2
TCGA-D9-A4Z2-01A 50 years, male, white, stage:Stage IIIC, dead, 190 days 795.1
TCGA-GN-A8LN-01A 68 years, male, white, stage:Stage IIC, alive, 772 days 779.6
TCGA-EB-A24C-01A 56 years, male, white, stage:'--, alive, 632 days 741.9
TCGA-EB-A3HV-01A 37 years, male, white, stage:Stage IIC, alive, 39 days 689.6
TCGA-EB-A6QY-01A 71 years, male, white, stage:Stage IIC, alive, 382 days 600.9
TCGA-WE-A8K4-01A 85 years, male, white, stage:Stage IIB, alive, 614 days 576.0
TCGA-FR-A2OS-01A 49 years, female, white, stage:Stage IIC, dead, 368 days 572.0
TCGA-YG-AA3N-01A 67 years, male, stage:Stage IIC, alive, 306 days 558.5
TCGA-EB-A553-01A 62 years, male, white, stage:Stage IIC, alive, 226 days 496.9
TCGA-EB-A3Y7-01A 86 years, female, white, stage:Stage IIIB, dead, 326 days 489.7
TCGA-EB-A5SF-01A 78 years, female, white, stage:Stage IIC, dead, 369 days 486.4
TCGA-EB-A3Y6-01A 56 years, female, white, stage:Stage IIC, alive, 126 days 313.4
TCGA-GN-A26C-01A 77 years, male, white, stage:Stage IIIC, dead, 821 days 191.3
TCGA-D9-A3Z4-01A 54 years, male, white, stage:Stage IIIC, dead, 519 days 100.5
TCGA-EB-A42Z-01A 49 years, male, asian, stage:Stage IIIC, alive, 441 days 0.0
Show allShow less
MELANOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA049719
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Malignant melanoma, NOS
Malignant melanoma, Metastatic site

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org